This Caterpillar Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Portfolio Pulse from Avi Kapoor
Several top Wall Street analysts have downgraded their ratings for major companies, including Caterpillar, Expeditors International, KeyCorp, Triumph Group, and Kura Oncology. These downgrades come with reduced price targets, indicating potential short-term impacts on their stock prices.
October 14, 2024 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley downgraded Caterpillar from Equal-Weight to Underweight, reducing the price target from $349 to $332. Despite the downgrade, shares closed at $402.02, up 1.4%.
The downgrade from Morgan Stanley and the reduced price target suggest a bearish outlook for Caterpillar, likely leading to a short-term negative impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
TD Cowen downgraded Expeditors International from Hold to Sell, lowering the price target from $112 to $106. Shares closed at $123.02, up 1.4%.
The downgrade to Sell and reduced price target indicate a negative outlook for Expeditors, likely causing a short-term decline in its stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
JP Morgan downgraded Triumph Group from Neutral to Underweight, cutting the price target from $15 to $12. Shares closed at $15.00, up 6.2%.
The downgrade to Underweight and significant reduction in price target suggest a bearish outlook for Triumph Group, likely leading to a short-term negative impact on its stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
Baird downgraded KeyCorp from Outperform to Neutral, reducing the price target from $18 to $17. Shares closed at $17.22, up 2.3%.
The downgrade to Neutral and slight reduction in price target suggest a more cautious outlook for KeyCorp, but the impact on the stock price may be neutral in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
NEUTRAL IMPACT
Stifel downgraded Kura Oncology from Buy to Hold, lowering the price target from $26 to $19. Shares closed at $18.58, up 1.9%.
The downgrade to Hold and reduced price target suggest a more cautious outlook for Kura Oncology, but the short-term impact on the stock price may be neutral.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100